FoxA1 corrupts the antiandrogenic effect of bicalutamide but only weakly attenuates the effect of MDV3100 (Enzalutamide™)

Molecular and Cellular Endocrinology

Volumn 365, Issue 1, 2013, Pages 95-107

  Belikov, S ^a   Oberg C ^a   Jaaskelainen T ^b   Rahkama, V ^b   Palvimo, J J ^b   Wrange, O ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Androgen receptor; Bicalutamide; Chromatin presetting; FoxA1; MDV3100 (Enzalutamide); Xenopus oocyte

Indexed keywords

ANDROGEN RECEPTOR; BICALUTAMIDE; DNA; ENZALUTAMIDE; HEPATOCYTE NUCLEAR FACTOR 3ALPHA;

ANIMAL CELL; ARTICLE; CANCER PROGNOSIS; CELL NUCLEUS; CELLULAR DISTRIBUTION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA BINDING; HUMAN; HUMAN CELL; IN VIVO STUDY; NONHUMAN; OOCYTE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; RECEPTOR BINDING; XENOPUS;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CELL NUCLEUS; CHROMATIN ASSEMBLY AND DISASSEMBLY; FEMALE; HEK293 CELLS; HEPATOCYTE NUCLEAR FACTOR 3-ALPHA; HUMANS; MALE; NEOPLASM PROTEINS; NITRILES; NONSTEROIDAL ANTI-ANDROGENS; OOCYTES; PHENYLTHIOHYDANTOIN; PROSTATE; PROSTATIC NEOPLASMS; PROTEIN TRANSPORT; RECEPTORS, ANDROGEN; RECOMBINANT PROTEINS; RNA INTERFERENCE; TOSYL COMPOUNDS; XENOPUS LAEVIS;

EID: 84868495700     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2012.10.002     Document Type: Article

References (56)

1. Almouzni G., Wolffe A.P. Replication-coupled chromatin assembly is required for the repression of basal transcription in vivo. Genes Dev. 1993, 7:2033-2047.
2. Amaral T.M., Macedo D., Fernandes I., Costa L. Castration-resistant prostate cancer: mechanisms, targets, and treatment. Prostate Cancer 2012, 2012:327253.
3. Astrand C., Belikov S., Wrange O. Histone acetylation characterizes chromatin presetting by NF1 and Oct1 and enhances glucocorticoid receptor binding to the MMTV promoter. Exp Cell Res. 2009, 315:2604-2615.
4. Balk S.P., Knudsen K.E. AR, the cell cycle, and prostate cancer. Nucl. Recept. Signal. 2008, 6:e001.
5. Belikov S., Gelius B., Almouzni G., Wrange O. Hormone activation induces nucleosome positioning in vivo. EMBO J. 2000, 19:1023-1033.
6. Belikov S., Gelius B., Wrange O. Hormone-induced nucleosome positioning in the MMTV promoter is reversible. EMBO J. 2001, 20:2802-2811.
7. Belikov S., Astrand C., Holmqvist P.H., Wrange O. Chromatin-mediated restriction of nuclear factor 1/CTF binding in a repressed and hormone-activated promoter in vivo. Mol. Cell Biol. 2004, 24:3036-3047.
8. Belikov S., Holmqvist P.H., Astrand C., Wrange O. Nuclear factor 1 and octamer transcription factor 1 binding preset the chromatin structure of the mouse mammary tumor virus promoter for hormone induction. J. Biol. Chem. 2004, 279:49857-49867.
9. Belikov S., Astrand C., Wrange O. Mechanism of histone H1-stimulated glucocorticoid receptor DNA binding in vivo. Mol. Cell Biol. 2007, 27:2398-2410.
10. Belikov S., Astrand C., Wrange O. FoxA1 binding directs chromatin structure and the functional response of a glucocorticoid receptor-regulated promoter. Mol. Cell Biol. 2009, 29:5413-5425.
11. Belikov S., Holmqvist P.H., Astrand C., Wrange O. FoxA1 and glucocorticoid receptor crosstalk via histone H4K16 acetylation at a hormone regulated enhancer. Exp. Cell Res. 2012, 318:61-74.
12. Buetti E., Diggelmann H. Cloned mouse mammary tumor virus DNA is biologically active in transfected mouse cells and its expression is stimulated by glucocorticoid hormones. Cell 1981, 23:335-345.
13. Chen C.D., Welsbie D.S., Tran C., Baek S.H., Chen R., Vessella R., Rosenfeld M.G., Sawyers C.L. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004, 10:33-39.
14. Cirillo L.A., Lin F.R., Cuesta I., Friedman D., Jarnik M., Zaret K.S. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell. 2002, 9:279-289.
15. Eeckhoute J., Carroll J.S., Geistlinger T.R., Torres-Arzayus M.I., Brown M. A cell-type-specific transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev. 2006, 20:2513-2526.
16. Gao N., Zhang J., Rao M.A., Case T.C., Mirosevich J., Wang Y., Jin R., Gupta A., Rennie P.S., Matusik R.J. The role of hepatocyte nuclear factor-3 alpha (Forkhead Box A1) and androgen receptor in transcriptional regulation of prostatic genes. Mol. Endocrinol. 2003, 17:1484-1507.
17. Gerhardt J., Montani M., Wild P., Beer M., Huber F., Hermanns T., Muntener M., Kristiansen G. FOXA1 promotes tumor progression in prostate cancer and represents a novel hallmark of castration-resistant prostate cancer. Am. J. Pathol. 2012, 180:848-861.
18. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., Asangani I.A., Ateeq B., Chun S.Y., Siddiqui J., Sam L., Anstett M., Mehra R., Prensner J.R., Palanisamy N., Ryslik G.A., Vandin F., Raphael B.J., Kunju L.P., Rhodes D.R., Pienta K.J., Chinnaiyan A.M., Tomlins S.A. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
19. Haendler B., Cleve A. Recent developments in antiandrogens and selective androgen receptor modulators. Mol. Cell Endocrinol. 2012, 352:79-91.
20. Holmqvist P.H., Belikov S., Zaret K.S., Wrange O. FoxA1 binding to the MMTV LTR modulates chromatin structure and transcription. Exp. Cell Res. 2005, 304:593-603.
21. Hu R., Dunn T.A., Wei S., Isharwal S., Veltri R.W., Humphreys E., Han M., Partin A.W., Vessella R.L., Isaacs W.B., Bova G.S., Luo J. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 2009, 69:16-22.
22. Huggins C., Hodges C.V. Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. CA Cancer J. Clin. 1972, 22:232-240.
23. Hurtado A., Holmes K.A., Ross-Innes C.S., Schmidt D., Carroll J.S. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 2011, 43:27-33.
24. Jaaskelainen T., Makkonen H., Visakorpi T., Kim J., Roeder R.G., Palvimo J.J. Histone H2B ubiquitin ligases RNF20 and RNF40 in androgen signaling and prostate cancer cell growth. Mol. Cell Endocrinol. 2012, 350:87-98.
25. Jackson A.L., Burchard J., Leake D., Reynolds A., Schelter J., Guo J., Johnson J.M., Lim L., Karpilow J., Nichols K., Marshall W., Khvorova A., Linsley P.S. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing. RNA 2006, 12:1197-1205.
26. Jain R.K., Mehta R.J., Nakshatri H., Idrees M.T., Badve S.S. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 2011, 58:766-772.
27. John S., Sabo P.J., Johnson T.A., Sung M.H., Biddie S.C., Lightman S.L., Voss T.C., Davis S.R., Meltzer P.S., Stamatoyannopoulos J.A., Hager G.L. Interaction of the glucocorticoid receptor with the chromatin landscape. Mol. Cell. 2008, 29:611-624.
28. John S., Sabo P.J., Thurman R.E., Sung M.H., Biddie S.C., Johnson T.A., Hager G.L., Stamatoyannopoulos J.A. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 2011, 43:264-268.
29. Kaestner K.H. The FoxA factors in organogenesis and differentiation. Curr. Opin. Genet Dev. 2010, 20:527-532.
30. Kelly W.K., Slovin S., Scher H.I. Steroid hormone withdrawal syndromes. Pathophysiology and clinical significance. Urol. Clin. North Am. 1997, 24:421-431.
31. Kim Y.S., Kumar V., Lee S., Iwai A., Neckers L., Malhotra S.V., Trepel J.B. Methoxychalcone inhibitors of androgen receptor translocation and function. Bioorg. Med. Chem. Lett. 2012, 22:2105-2109.
32. Li J., Fu J., Toumazou C., Yoon H.G., Wong J. A role of the amino-terminal (N) and carboxyl-terminal (C) interaction in binding of androgen receptor to chromatin. Mol. Endocrinol. 2006, 20:776-785.
33. Li Z., Tuteja G., Schug J., Kaestner K.H. Foxa1 and Foxa2 are essential for sexual dimorphism in liver cancer. Cell 2012, 148:72-83.
34. Lupien M., Eeckhoute J., Meyer C.A., Wang Q., Zhang Y., Li W., Carroll J.S., Liu X.S., Brown M. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970.
35. Lutz L.B., Cole L.M., Gupta M.K., Kwist K.W., Auchus R.J., Hammes S.R. Evidence that androgens are the primary steroids produced by Xenopus laevis ovaries and may signal through the classical androgen receptor to promote oocyte maturation. Proc. Natl. Acad. Sci. USA 2001, 98:13728-13733.
36. Makkonen H., Jaaskelainen T., Pitkanen-Arsiola T., Rytinki M., Waltering K.K., Matto M., Visakorpi T., Palvimo J.J. Identification of ETS-like transcription factor 4 as a novel androgen receptor target in prostate cancer cells. Oncogene 2008, 27:4865-4876.
37. Makkonen H., Kauhanen M., Jaaskelainen T., Palvimo J.J. Androgen receptor amplification is reflected in the transcriptional responses of Vertebral-Cancer of the Prostate cells. Mol. Cell Endocrinol. 2011, 331:57-65.
38. Payvar F., Wrange O., Carlstedt-Duke J., Okret S., Gustafsson J.A., Yamamoto K.R. Purified glucocorticoid receptors bind selectively in vitro to a cloned DNA fragment whose transcription is regulated by glucocorticoids in vivo. Proc. Natl. Acad. Sci. USA 1981, 78:6628-6632.
39. Richard-Foy H., Hager G.L. Sequence-specific positioning of nucleosomes over the steroid-inducible MMTV promoter. EMBO J. 1987, 6:2321-2328.
40. Rigaud G., Roux J., Pictet R., Grange T. In vivo footprinting of rat TAT gene: dynamic interplay between the glucocorticoid receptor and a liver-specific factor. Cell 1991, 67:977-986.
41. Rytinki, M., Kaikkonen, S., Sutinen, P., Paakinaho, V., Rahkama, V. Palvimo, J.J., 2012. Dynamic SUMOylation is linked to the activity cycles of androgen receptor in the cell nucleus. Mol. Cell Biol.
42. Sahu B., Laakso M., Ovaska K., Mirtti T., Lundin J., Rannikko A., Sankila A., Turunen J.P., Lundin M., Konsti J., Vesterinen T., Nordling S., Kallioniemi O., Hautaniemi S., Janne O.A. Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer. EMBO J. 2011, 30:3962-3976.
43. Shogren-Knaak M., Ishii H., Sun J.M., Pazin M.J., Davie J.R., Peterson C.L. Histone H4-K16 acetylation controls chromatin structure and protein interactions. Science 2006, 311:844-847.
44. Siersbaek R., Nielsen R., John S., Sung M.H., Baek S., Loft A., Hager G.L., Mandrup S. Extensive chromatin remodelling and establishment of transcription factor 'hotspots' during early adipogenesis. EMBO J. 2011, 30:1459-1472.
45. So A.Y., Chaivorapol C., Bolton E.C., Li H., Yamamoto K.R. Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet. 2007, 3:e94.
46. Thompson J., Saatcioglu F., Janne O.A., Palvimo J.J. Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol. Endocrinol. 2001, 15:923-935.
47. Tran C., Ouk S., Clegg N.J., Chen Y., Watson P.A., Arora V., Wongvipat J., Smith-Jones P.M., Yoo D., Kwon A., Wasielewska T., Welsbie D., Chen C.D., Higano C.S., Beer T.M., Hung D.T., Scher H.I., Jung M.E., Sawyers C.L. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009, 324:787-790.
48. van de Wijngaart D.J., Dubbink H.J., van Royen M.E., Trapman J., Jenster G. Androgen receptor coregulators: recruitment via the coactivator binding groove. Mol. Cell Endocrinol. 2012, 352:57-69.
49. Wang Q., Li W., Liu X.S., Carroll J.S., Janne O.A., Keeton E.K., Chinnaiyan A.M., Pienta K.J., Brown M. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol. Cell. 2007, 27:380-392.
50. Wang Q., Li W., Zhang Y., Yuan X., Xu K., Yu J., Chen Z., Beroukhim R., Wang H., Lupien M., Wu T., Regan M.M., Meyer C.A., Carroll J.S., Manrai A.K., Janne O.A., Balk S.P., Mehra R., Han B., Chinnaiyan A.M., Rubin M.A., True L., Fiorentino M., Fiore C., Loda M., Kantoff P.W., Liu X.S., Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
51. Wilson E.M. Analysis of interdomain interactions of the androgen receptor. Methods Mol. Biol. 2011, 776:113-129.
52. Wong C.I., Zhou Z.X., Sar M., Wilson E.M. Steroid requirement for androgen receptor dimerization and DNA binding. Modulation by intramolecular interactions between the NH2-terminal and steroid-binding domains. J. Biol. Chem. 1993, 268:19004-19012.
53. Yang W.H., Lutz L.B., Hammes S.R. Xenopus laevis ovarian CYP17 is a highly potent enzyme expressed exclusively in oocytes. Evidence that oocytes play a critical role in Xenopus ovarian androgen production. J. Biol. Chem. 2003, 278:9552-9559.
54. Zaret K.S., Yamamoto K.R. Reversible and persistent changes in chromatin structure accompany activation of a glucocorticoid-dependent enhancer element. Cell 1984, 38:29-38.
55. Zaret K.S., Carroll J.S. Pioneer transcription factors: establishing competence for gene expression. Genes Dev. 2011, 25:2227-2241.
56. Zernicka-Goetz M., Pines J., Ryan K., Siemering K.R., Haseloff J., Evans M.J., Gurdon J.B. An indelible lineage marker for Xenopus using a mutated green fluorescent protein. Development 1996, 122:3719-3724.